Abstracts Archive - Page 583 of 1683 - ATC Abstracts

2019 American Transplant Congress
Hepatitis A Hospitalizations among Kidney Transplant Recipients in the United States: A Nationwide Study
W. Cheungpasitporn¹, C. Thongprayoon², P. Ungprasert³, K. Wijarnpreecha⁴, P. T. Kroner⁴
¹Nephrology, University of Mississippi Medical Center, Jackson, MS, ²Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Nephrology, University of Mississippi Medical Center, Bangkok, Thailand, ⁴Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
*Purpose: Hepatitis A illness severity increases in immunosuppressed patients and one of important indicators of hepatitis A illness severity is whether patients require hospitalization. This…
2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
C. Durand, B. Barnaba, D. Brown, N. Bair, F. Naqvi, M. Bowring, D. Segev, M. Sulkowski, N. Desai
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…
2019 American Transplant Congress
Introduction of Universal Hepatitis E RNA Screening in Deceased Organ Donors – The UK Experience
I. Ushiro-Lumb¹, K. Tettmar¹, I. Johannessen², K. Simpson², I. Hart³, J. Timms⁴, A. Hale⁵, S. Ijaz⁶, R. Tedder⁶, J. Forsythe¹
¹NHS Blood and Transplant, London, United Kingdom, ²Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, ³Royal Liverpool University Hospital, Liverpool, United Kingdom, ⁴University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ⁵Public Health England, Leeds, United Kingdom, ⁶Public Health England, London, United Kingdom
*Purpose: We aim to describe the strategy and initial results of post-donation, universal screening of deceased organ donors in the UK. HEV RNA is tested…
2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
P. Brown¹, Z. Demertzis¹, S. Jafri²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…
2019 American Transplant Congress
Evaluating Hepatitis C Treatment after Solid Organ Transplantation
A. J. Burgos¹, R. Yau¹, C. Tunwar², J. A. Goss³, S. Khaderi³, N. L. Sussman⁴
¹Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ²CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ³Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, ⁴Abdominal Transplant & Liver Disease, Baylor College of Medicine, Houston, TX
*Purpose: There is limited data on the use of direct acting antivirals for hepatitis C virus (HCV) in the solid organ transplant (SOT) population. The…
2019 American Transplant Congress
Listing Practices and Graft Utilization Lag behind Supply of Hepatitis C Positive Deceased Donors for Liver and Kidney Transplant
C. E. Kling¹, J. D. Perkins², S. W. Biggins³, C. Johnson⁴, A. P. Limaye⁵, L. Sibulesky¹
¹Division of Transplant Surgery, University of Washington Medical Center, Seattle, WA, ²Division of Transplant Surgery and Clinical and Bio-Analytics Transplant Laboratory, University of Washington Medical Center, Seattle, WA, ³Divisions of Gastroenterology and Hepatology and Center for Liver Investigation Fostering DiscovEry, University of Washington Medical Center, Seattle, WA, ⁴Division of Nephrology, University of Washington Medical Center, Seattle, WA, ⁵Division of Infectious Disease, University of Washington Medical Center, Seattle, WA
*Purpose: The opioid epidemic resulted in increasing incidence of hepatitis C (HCV) in the general population and more deceased organ donors with HCV in the…
2019 American Transplant Congress
Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation
J. Wellington¹, A. Ma², S. Kottilil³, J. Husson³, E. Wilson³, D. Bruno⁴
¹Gastroenterology & Hepatology, University of Maryland, Baltimore, MD, ²Internal Medicine, University of Maryland, Baltimore, MD, ³Institute of Human Virology, Division of Clinical Care and Research, University of Maryland, Baltimore, MD, ⁴Transplant Surgery, University of Maryland, Baltimore, MD
*Purpose: Liver transplantation, LT, for HCV-related disease has the lowest five-year graft survival of all LT recipients, primarily due to accelerated fibrosis from unrestrained HCV…
2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…
2019 American Transplant Congress
Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience
A. Sharfuddin, S. A. Hussain, T. Taber, D. Mishler, O. Adebiyi, M. S. Yaqub
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. We…
2019 American Transplant Congress
Redox State of HMGB1 Drives Ischemia-Reperfusion Injury in Human Liver Transplantation
R. A. Sosa¹, A. Q. Terry¹, J. Nevarez-Mejia¹, M. Rossetti¹, B. V. Naini¹, V. M. Groysberg¹, F. M. Kaldas², R. W. Busuttil², D. W. Gjertson¹, J. W. Kupiec-Weglinski², E. F. Reed¹
¹Pathology & Laboratory Medicine, UCLA, Los Angeles, CA, ²Surgery, UCLA, Los Angeles, CA
*Purpose: Ischemia-reperfusion injury (IRI) is a major risk factor of acute and chronic graft rejection in orthotopic liver transplantation (OLT) involving a complex interplay between…